Autopsy report · NCT00736450

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

“Manufacturer is no longer making the drug.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 3 months before it stopped.
• 37 participants enrolled.
• Results were posted on the registry 5 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

University of Nebraska

Sponsor type

University, hospital or other

Conditions

Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma

Interventions

oblimersen sodium; rituximab; cyclophosphamide; doxorubicin hydrochloride; vincristine sulfate; prednisone

Participants

37

Sites

2

Countries

United States

Trials that died the same way

• A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis
  “Drug manufacturer ceased operations” (80% match in meaning)
• Active Surveillance Post-Approval Atudy of the Stelkast Surpass Acetabular System
  “Product is no longer being manufactured and marketed.” (78% match in meaning)
• Phase I Study of CS-7017 and Bexarotene
  “Drug no longer available” (74% match in meaning)
• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
  “Drug was no longer available” (71% match in meaning)
• CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
  “The pharmaceutical funder pulled funding and no longer plans to develop the drug further.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.